Eosinophils and melanoma: Implications for immunotherapy.

Area of Science:

• Oncology
• Immunology
• Hematology

Background:

• Advanced melanoma survival is improved by immune checkpoint blockers (ICB).
• ICBs cause significant side effects across multiple organ systems.
• Current biomarkers for ICB tolerance are limited by heterogeneity and clinical translation challenges.

Purpose of the Study:

• To review eosinophil functionality and their role in melanoma.
• To discuss how eosinophils may influence response to ICBs.
• To explore the clinical implications of eosinophils in advanced melanoma treatment.

Main Methods:

• Literature review of eosinophil function in cancer.
• Analysis of observational studies linking eosinophils to melanoma survival.
• Discussion of potential mechanisms of eosinophil-mediated ICB response.

Main Results:

• Eosinophil counts and eosinophil cationic protein levels correlate with prolonged survival in advanced melanoma.
• Eosinophils may play a complex role in modulating tumor immunity and treatment response.
• Emerging evidence suggests eosinophils as potential predictive biomarkers for ICB therapy.

Conclusions:

• Eosinophils represent a promising area for understanding and improving ICB efficacy in melanoma.
• Further investigation into eosinophil mechanisms is crucial for clinical application.
• Targeting or leveraging eosinophils could optimize advanced melanoma treatment strategies.